These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31000132)

  • 1. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.
    Ojal J; Griffiths U; Hammitt LL; Adetifa I; Akech D; Tabu C; Scott JAG; Flasche S
    Lancet Glob Health; 2019 May; 7(5):e644-e654. PubMed ID: 31000132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya.
    Flasche S; Ojal J; Le Polain de Waroux O; Otiende M; O'Brien KL; Kiti M; Nokes DJ; Edmunds WJ; Scott JAG
    BMC Med; 2017 Jun; 15(1):113. PubMed ID: 28592303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
    Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
    Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
    Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study.
    Chen C; Ang G; Akksilp K; Koh J; Scott JAG; Clark A; Jit M
    Lancet Glob Health; 2024 Sep; 12(9):e1485-e1497. PubMed ID: 39151983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
    Kim SY; Lee G; Goldie SJ
    BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.
    Chen C; Cervero Liceras F; Flasche S; Sidharta S; Yoong J; Sundaram N; Jit M
    Lancet Glob Health; 2019 Jan; 7(1):e58-e67. PubMed ID: 30554762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
    Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
    BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL; Etyang AO; Morpeth SC; Ojal J; Mutuku A; Mturi N; Moisi JC; Adetifa IM; Karani A; Akech DO; Otiende M; Bwanaali T; Wafula J; Mataza C; Mumbo E; Tabu C; Knoll MD; Bauni E; Marsh K; Williams TN; Kamau T; Sharif SK; Levine OS; Scott JAG
    Lancet; 2019 May; 393(10186):2146-2154. PubMed ID: 31000194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
    Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
    Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.
    Che D; Zhou H; He J; Wu B
    BMC Health Serv Res; 2014 Feb; 14():56. PubMed ID: 24507480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
    Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
    East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustainability of pneumococcal conjugate vaccination in Ghana: a cost-effectiveness analysis in the context of donor transition.
    Ibrahim AM; Owusu R; Nonvignon J
    Front Public Health; 2024; 12():1383668. PubMed ID: 39148654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.